Sri/surgical Express, Inc. (STRC) reported Q4 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.35 million.
Sarcos ended the year with $217 million in unrestricted cash and cash equivalents on its balance sheet. An increase from $34 million at the end of 2020 due to the proceeds from the companys business combination in September.
For earnings history and earnings-related data on Sri/surgical Express, Inc. (STRC) click here.